AIE‐Active Antibacterial Photosensitizer Disrupting Bacterial Structure: Multicenter Validation against Drug‐Resistant Pathogens.

Antimicrobial resistance (AMR) has emerged as a global challenge in treating bacterial infections, creating an urgent need for broad‐spectrum antimicrobial agents that can effectively combat multidrug‐resistant (MDR) bacteria. Despite advancements in novel antimicrobial agents, many fail to comprehensively cover common resistant bacterial strains or undergo rigorous multi‐center validation. Herein, a cationic AIE‐active photosensitizers are developed, ITPM, derived from a triphenylamine‐pyridine backbone to address the MDR challenge. Rigorous validation demonstrates that ITPM possesses superior fluorescence imaging capabilities and exceptional antibacterial efficacy. And its broad‐spectrum activity is verified through a multi‐center study involving six clinically relevant MDR strains. Additionally, resistance development studies and comparisons with advanced clinical antibiotics reveal that ITPM exhibits potent, broad‐spectrum antimicrobial activity with minimal resistance development. This efficacy is attributed to its unique antibacterial mechanism involving disrupting bacterial internal structures. These findings establish ITPM as a promising candidate for broad‐spectrum antimicrobial therapy, offering a potential solution to the growing crisis of AMR in clinical settings. [ABSTRACT FROM AUTHOR]